Organisation paid for research Program year 2025 Source: CMS Open Payments

Arizona Eye Center

Neither a doctor nor a teaching hospital

Research payments

$856,978

221 payments

Through program year 2025, Arizona Eye Center is reported as receiving $856,978 in research payments, across 221 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $289,907 15
2024 Research $56,356 2
2023 Research $456,725 12
2022 Research $14,909 6
2020 Research $21,173 124
2019 Research $17,908 62

Breakdown

Who paid Research payments · program years 2019–2025
  1. Bausch & Lomb Americas Inc. $504,063 8 payments
  2. Oyster Point Pharma, Inc. $289,907 15 payments
  3. Allergan Inc. $37,465 185 payments
  4. AbbVie, Inc. $23,927 12 payments
  5. Novartis Pharmaceuticals Corporation $1,616 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution, Used Two Times Daily in Healthy $504,063 8 payments
  2. Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) $242,333 12 payments
  3. OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) $47,574 3 payments
  4. Long-term Safety and Efficacy Extension Trial of Bimatoprost SR $23,927 12 payments
  5. A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension $15,663 83 payments
  6. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patient with Open Angle Glaucoma or Ocular Hypertension $7,435 26 payments
  7. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $7,211 59 payments
  8. Efficacy and Safety of Bimatoprost Sustained-Release Sr in Patients With Open-Angle Glaucoma Or Ocular Hypertension $5,186 13 payments
  9. Efficacy and Safety of Bimatoprost Sustained-Release (Sr) in Patients With Open-Angle Glaucoma Or Ocular Hypertension $1,970 4 payments
  10. A Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Efficacy of Ecf843 VS Vehicle in Subjects With Dry Eye Disease $1,616 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record